Houston Rx LLC, Houston, TX
Is Houston Rx LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Houston Rx LLC hold a Texas pharmacy license?
The Texas State Board of Pharmacy lists license 35757 for HOUSTON RX, HOUSTON, status Active, as of Nov 15, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 7971 for Houston RX, Houston, TX, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054023272 for HOUSTON RX, HOUSTON, TX, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0004497 for HOUSTON RX, HOUSTON, TX, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0013229 for Houston Rx, HOUSTON, TX, status Active, as of Nov 10, 2026.
Has Houston Rx LLC had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Aug 28, 2026) for Houston Rx LLC. State board actions: the Texas State Board of Pharmacy file dated Nov 15, 2026 does not mark prior disciplinary orders on license 35757. The Colorado State Board of Pharmacy’s license dataset also lists “CLS Stipulation” dated Feb 3, 2026, case 2024-9870 on nonresident license OSP 7971.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Houston Rx LLC
- Location
- Houston, TX
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Aug 28, 2026
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 14 observations
- State board records
- License found: 35757, Active
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Houston Rx LLC, a 503A facility, with 1 dated action.
| Document | |||
|---|---|---|---|
| Aug 28, 2026 | Form 483 | 483 Issued 08/28/2026 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 14 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 20, 2026 to Aug 28, 2026: 14 observations
- Firm on the cover
- Houston Rx LLC, 15340 Vantage Pkwy E Ste 220, Houston, TX 77032-1901
- FEI number
- 3045022201
- Establishment type on the cover
- Producer of Sterile Drugs
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Personnel performed aseptic manipulations with exposed hair or skin.
Specifically, on August 24, 2026, while filling/stoppering lot #SMN-082426-5/2-5 of Semaglutide/Niacinamide 5mg/2mg/1 ml, we observed one of the operators working in the ISO 5 laminar flow hood with exposed skin on her forehead. The operator was observed entering the ISO 5 LFH, leaning over the bag of sterilized stoppers within the ISO 5 LFH, and placing stoppers on the recently filled vials.
Observation 2
Specifically, from July 10, 2026 to August 21 , 2026, your system for measuring pressure differential in the cleanrooms indicates negative pressure between the ISO 7 Buffer Room where the ISO 5 Laminar Flow Hoods are located and the ISO 8 Ante Room. The specification is <Redacted B4> w.c. and every data point documented in this time period was below 0.00" w.c. Your firm has made at least <Redacted B4> lots of various drug products in this time period. All have been released.
Observation 3
Inadequate <Redacted B4> testin g on <Redacted B4> used to sterilize drug products.
Specifically, your firm is not conducting <Redacted B4> testing <Redacted B4> appropriately as recommended by the <Redacted B4> manufacturer. Your firm has not identified an appropriate <Redacted B4> agent and you do not <Redacted B4> the <Redacted B4> before testing. <Redacted B4>, you attach <Redacted B4> to one end of the <Redacted B4> and attach the other end of the <Redacted B4> to a <Redacted B4>. You then <Redacted B4> the <Redacted B4> in <Redacted B4> of <Redacted B4> from the <Redacted B4> through the <Redacted B4> and look for <Redacted B4>. On August 24, 2026, we watched <Redacted B4> testing of the <Redacted B4> used in the preparation of lot #SMN-082426-5/2-5 of Semaglutide/Niacinamide 5mg/2mg/1 ml performed in this manner.
Observation 4
Personnel were observed manually contacting the inner surface of a sterile container or closure and manually touching a sterile product contact surface.
Specifically, on August 24, 2026, we watched the filling and stoppering of lot #SMN-082426-5/2-5 of Semaglutide/Niacinamide 5mg/2mg/1ml. Your practice is to place the sterile stoppers onto the filled vials using <Redacted B4> and then pressing down on the stoppers with your <Redacted B4> to push the stopper into the vial.
Observation 5
Microbial contamination was present in the ISO 5 area.
On August 3, 2026, your firm recovered 1 CFU in the ISO 5 Laminar Flow Hood <Redacted B4> (viable surface sample) after the filling/stoppering of lot #TZN-080326-20/2-2 of Tirzepatide/Niacinamide 20/2 mg/ml (2ml vial). No investigation was performed as your firm's action level for ISO 5 areas is <Redacted B4> CFU, which is not appropriate. The lot was released and has been partially distributed.
Observation 6
The facility is designed and/or operated in a way that permits poor flow of personnel or materials.
Specifically, technicians enter the ISO 8 cleanroom area via a door from the unclassified <Redacted B4> area. Gowning occurs in the ISO 8 area, including washing of hands, on the "clean" side of the demarcation line. There is no designated room or area for gowning. Employees who are gowned and not gowned can interact in the same space while gowning. After formulation, those employees will then enter the ISO 7 cleanroom and work in the ISO 5 hood preparing sterile drug products without changing their garb except for their sterile gloves.
Observation 7
Sterile drugs were exposed to lower than ISO 5 quality air.
Specifically, on August 24, 2026, we watched the filling and stoppering of lot #SMN-082426-5/2-5 of Semaglutide/Niacinamide 5mg/2mg/1ml. Your practice is to place the sterile stoppers onto the filled vials using <Redacted B4> and then pressing down on the stoppers with your <Redacted B4> to push the stopper into the vial. You then <Redacted B4> of the vials with <Redacted B4> the <Redacted B4> and take them out of the cleanroom. They may be stored overnight in the <Redacted B4> <Redacted B4> of the vials, which is the final step to finish the closing of the vials, occurs in the unclassified area of the <Redacted B4>.
Observation 8
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically, typical batch sizes for Semaglutide/Niacinamide and Tirzepatide/Niacinamide drug products are <Redacted B4> vials. Vial sizes can range from 1ml to 5ml for GLP1 products and up to 10ml for other drug products. Production includes <Redacted B4> the drug product into a sterile <Redacted B4> filling vials from the <Redacted B4> of <Redacted B4> drug product using a <Redacted B4>, and then manually placing stoppers on the vials. During a media fill, per your Quality Assurance/Compliance Pharmacy Technician, your firm fills <Redacted B4> vials. Your firm takes prepared media from a vial, draws it into a <Redacted B4> for <Redacted B4>, and then fills the vials using the <Redacted B4>. 1. Your firm also does not document the number of vials filled, incubated and read in the paperwork for the media fills.
Observation 9
Use of ingredients not intended for pharmaceutical use in sterile drug production.
Specifically, your firm is using active pharmaceutical ingredients and excipients that are not always USP/NF grade or are non-pharmaceutical grade. For example,
a) The Certificate of Analysis (CoA) for Lot # <Redacted B4> of Methylcobalamin states "For R&D only". Your firm has made approximately <Redacted B4> lots of Methylcobalamin 5mg/ml using lot# <Redacted B4> for <Redacted B4>.
b) The CoA for lot <Redacted B4> of Tirzepatide states it is for "R&D only". Your firm has made approximately <Redacted B4> (lots of Tirzepatide/Niacinamide 10/2 mg/ml and <Redacted B4> lots of Tirzepatide/Niacinamide 20/2 mg/ml using lot <Redacted B4> of Tirzepatide.
Tirzepatide/Niacinamide 20/2 mg/ml using lot l((o) (4) I of Tirzepatide.
c) The CoA for lot # <Redacted B4> of Sermorelin states "This product is intended for scientific research use only". Your firm has made approximately <Redacted B4> lots of Sermorelin 1 mg/ml using lot # <Redacted B4>
d) The CoA for lot # <Redacted B4> of Semaglutide API states it is for "R&D only". ...
Observation 10
Contamination was observed in your areas adjacent to production areas.
Specifically, a ceiling vent just outside the cleanroom has water stains and what appears to be mold. On August 24, 2026, the vent was dripping condensate near the area where items to be taken into the cleanroom were wiped down for use in making lot #SMN-082426-5/2-5 of Semaglutide/Niacinamide 5mg/2mg/1 ml.
Observation 11
Use of cleaning and disinfecting agents that may leave residues or not adequately rinsing such agents from containers, closures, or equipment that come into direct contact with drug products.
Specifically, your firm uses <Redacted B4> and tap water to wash equipment used to make sterile drug products, including glass beakers, stir bars, and graduated cylinders. Your firm rinses the equipment with <Redacted B4> sterile water and then wipes the beakers and stir bars with <Redacted B4>. There is no wiping down of the inside of the graduated cylinders with <Redacted B4>. The graduated cylinders are used to measure out liquids such as the sterile water used during the production of sterile drug products. On August 24, 2026, we watched the cleaning of equipment to be used in the making of lot #SMN-082426-5/2-5 of Semaglutide/Niacinamide 5mg/2mg/1 ml, using this process.
Observation 12
Sterile products were exposed to non-sterile or non-depyrogenated supplies.
Specifically, your firm does not sterilize/depyrogenate the glass beakers, <Redacted B4> graduated cylinders, and stir bars used to make sterile drug products. On August 24, 2026, we watched the preparation of lot #SMN-082426-5/2-5 of Semaglutide/Niacinamide 5mg/2mg/1 ml. The glass beakers, <Redacted B4> graduated cylinders and stir bars were not sterilized/depyrogenated before use.
Observation 13
Biological indicators were not used to verify the adequacy of the sterilization cycle.
Specifically, your firm has not validated nor do you use a biological indicator (Bl) when <Redacted B4> the <Redacted B4> and <Redacted B4> used in the preparation of sterile drug products. The <Redacted B4> are used to place sterile stoppers onto the filled vials. <Redacted B4> are used to <Redacted B4> the <Redacted B4> of sterile water used in the formulation of sterile drug products.
Observation 14
Your firm is not storing active pharmaceutical ingredients (API) per the labeled storage conditions.
All APls are stored in a <Redacted B4> refrigerator. Examples of APls used in the production of sterile drug products that are not stored according to the labeled storage conditions include the following. Sterile drug products made with these APls have been released and distributed.
a) The CoA for lot <Redacted B4> of Semaglutide API states to store at <Redacted B4>. Your firm has made at least <Redacted B4> lots of Semaglutide/Niacinamide 2.5/2 mg/ml and <Redacted B4> lots of Semaglutide/Niacinamide 5/2 mg/ml using lot # <Redacted B4>
b) The CoA for lot # <Redacted B4> of Tirzepatide API states to store at <Redacted B4>. Your firm has made approximately <Redacted B4> lots of Tirzepatide/Niacinamide 10/2 mg/ml: and <Redacted B4> lots of Tirzepatide/Niacinamide 20/2 mg/ml using lot <Redacted B4> of Tirzepatide.
c) The CoA for lot# <Redacted B4> of Tirzepatide API states to store at <Redacted B4>
d) The CoA for lot# <Redacted B4> of Sermorelin API states to store at <Redacted B4> ...
State board of pharmacy records
The Texas State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status | Prior disciplinary orders (file flag) |
|---|---|---|---|---|---|
| 35757 | Community Sterile Compounding | HOUSTON RX | HOUSTON | Active | No |
What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 7971 | OSP | Houston RX | Houston, TX | Active |
- Feb 3, 2026: “CLS Stipulation”, license OSP 7971, case 2024-9870, Houston RX, Houston, TX. Board document
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054023272 | LICENSED PHARMACY | HOUSTON RX | HOUSTON, TX | ACTIVE |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0004497 | NONRESIDENT PHARMACY | HOUSTON RX | HOUSTON, TX | ACTIVE (CURRENT) |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0013229 | Non Resident Pharmacy | Houston Rx | HOUSTON, TX | Active |
GLP-1 warning letters
FDA’s posted warning letters that name a GLP-1 drug include 0 letters to Houston Rx LLC. See the Houston Rx LLC record page for those letters and any recalls.
No FDA warning letters in this index.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA warning letters (fda.gov full-text search)
- Texas State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Texas State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.